Prior to Simian Immunodeficiency Virus (SIV)-infected macaques becoming the 'model of choice' in the 1990s, chimpanzees were widely used in AIDS vaccine research and testing. Faced with the continued failure to develop an effective human vaccine, some scientists are calling for a return to their widespread use. To assess the past and potential future contribution of chimpanzees to AIDS vaccine development, databases and published literature were systematically searched to compare the results of AIDS vaccine trials in chimpanzees with those of human clinical trials, and to determine whether the chimpanzee trials were predictive of the human response. Protective and/or therapeutic responses have been elicited in chimpanzees, via: passive antibody transfer; CD4 analogues; attenuated virus; many types and combinations of recombinant HIV proteins; DNA vaccines; recombinant adenovirus and canarypox vaccines; and many multi-component vaccines using more than one of these approaches. Immunogenicity has also been shown in chimpanzees for vaccinia-based and peptide vaccines. Protection and/or significant therapeutic effects have not been demonstrated by any vaccine to date in humans. Vaccine responses in chimpanzees and humans are highly discordant. Claims of the importance of chimpanzees in AIDS vaccine development are without foundation, and a return to the use of chimpanzees in AIDS research/vaccine development is scientifically unjustifiable.
Introduction
Over decades, billions of dollars have been dedicated to the development of an AIDS vaccine, only to result in disappointment and failure (1, 2) . The exact number of vaccines tested pre-clinically and clinically is difficult to determine, but recent reviews have suggested over 30-40 vaccines in over 85 clinical trials involving almost 20,000 volunteers (3) (4) (5) (6) (7) . The US National Institute of Allergy and Infectious Diseases (NIAID) report over 50 preventive vaccines in over 100 clinical trials (8) , and 30plus therapeutic trials. This analysis indicates that the figures are even greater, with no vaccine affecting disease progression (9, 10) or approved for use.
Initial optimism, such as that shown in 1984 when the US Health and Human Services secretary declared that a vaccine would be available within two years, has given way to a realisation that the virus will not be beaten easily. In some quarters, it is acknowledged that animal models of questionable relevance are culpable (for comprehensive cited examples and examples of expert opinion, see [11] and other cited references throughout this review). These animal models include the use of macaques infected with Simian Immunodeficiency Virus (SIV) or hybrids of SIV and Human Immunodeficiency Virus (HIV). President Clinton's 2007 goal for the development of an AIDS vaccine has now passed, with notable high-profile failures such as VaxGen's AIDSVAX and Merck's V520 vaccines. In 2004, the AIDS Vaccine Advocacy Coalition (AVAC) acknowledged that there would be no vaccine available by 2007, foreseeing a 'long haul' (12) ; and optimistic experts predict that it will be over a decade before the first vaccine is available -while others predict half a century (13) .
In the light of these statistics and recent highprofile failures, many scientists are advocating changes to AIDS vaccine development. A small number involved in chimpanzee research believe that chimpanzees have been, and will remain, important, and thus advocate a return to their use (14) .
This recommendation requires evidence that chimpanzees played a crucial role when their use in the late 1980s and early 1990s was common. This is the scope of this study: to assess whether their responses to previous vaccines correlated with human responses and to compare the immunogenic and prophylactic natures of those vaccines in chimpanzees and humans. The a priori argument is that if the vaccines behaved similarly, the resumed use of chimpanzees may be scientifically justifiable, independent of ethical considerations; but if the chimpanzee results proved erroneously predictive, there would be no scientific basis upon which to call for the reinstatement of chimpanzees in AIDS research.
Summary of Vaccines and Clinical Trials
A prerequisite for comparing human and chimpanzee responses to AIDS vaccines is a comprehensive assessment of which vaccines have been involved in clinical trials to date. This was achieved by consulting the National Library of Medicine's ClinicalTrials.gov database (http://www.clinicaltrials.gov/), for which registration of clinical trials has been required for several years by the International Committee of Medical Journal Editors. The search was performed by using the operators 'AIDS OR HIV' (Disease or Condition field), and 'Vaccine' (Experi mental Treatment field). It included all trials that were no longer recruiting patients. Though this database may not constitute an exhaustive repository of information regarding all trials of HIV vaccines to date, it currently describes around 47,000 trials sponsored by the National Institutes of Health (NIH), other US federal agencies and private industry, conducted in 151 countries. For the purposes of this investigation, it can be regarded as the most complete source of HIV clinical trial data which is readily available. The International AIDS Vaccine Initiative (IAVI) database (http://www. iavireport. org/trialsdb/default.asp) was also used to obtain vaccine details.
All the clinical trials located are summarised in Table 1 . The 197 clinical trials of AIDS vaccines registered involved 85 different vaccine products (strain specificity of recombinant proteins, for example, was taken into account, meaning that strain MN recombinant gp120 was considered to be a separate vaccine from strain SF-2 recombinant gp120). Figure 1 indicates the types and prevalence of vaccines tested clinically in the 197 trials: 49 trials (25%) were of recombinant protein vaccines; 41 trials (21%) were of recombinant microbial vaccines (RMVs); and 50 trials (25%) used a combination of two or more approaches. These trials and the others constituting the remaining 29%, are discussed below. Figure 2 provides a breakdown of the types of vaccines in the RMV class. Of 41 trials, 13 (32%) involved canarypox vectors, closely followed by adenovirus vectors (12 trials [29%] ). Eight trials (20%) were based on vaccinia virus vaccines, and the remaining 19% involved a variety of viruses and bacteria, as detailed in the text.
Of the trials, 143 (72%) were Phase I trials ( Figure 3 ), which involve a relatively small number of volunteers (typically 20-100) over a two-year period, in which humans encounter the vaccine for the first time. Twenty-four (12%) were Phase II trials, in which vaccine candidates that appeared promising in Phase I investigations are tested in up to 300 people, including those at high risk of HIV infection or who are HIV-positive (HIV + ). Sixteen (8%) Phase I/II trials were also registered (i.e. Phase I and Phase II trials performed in parallel).
Just seven of the 197 clinical trials progressed to Phase III (the final stage of testing prior to licens- ing), in which the vaccine is tested typically in up to 3000 people, involving individuals at higher risk. A further seven trials did not specify the phase. Figure 4 summarises the status of the registered trials as of summer 2007. A total of 106 trials (54%) had reached an end, of which 95 trials (48% of the total) had been completed, with a further ten terminated and one suspended. Fifty-eight trials (29%) were 'no longer recruiting'; 33 were either actively, or about to begin, recruiting (24 trials and nine trials, respectively).
Detailed Analysis and Human Versus Chimpanzee Comparison
Vaccines and clinical trials were analysed in detail to assess whether those that failed in humans provided protection from HIV infection and/or therapeutic benefits in chimpanzees. A comprehensive analysis was performed of the recent history and current situation surrounding vaccine development in chimpanzees (see Table 2 for trial information) and humans (Table 1) , and to compare results and information from each species. Full use was made of the Nonhuman Primate HIV/SIV Vaccine Trials (NHPVT) Database (http://www.hiv.lanl.gov/content/ vaccine/home.html). In these Tables, the interventions are shown in plain text, underlined, or bold text, to indicate which specific vaccines were tested in both species (see Table legends ).
Passive approaches
Many of the early experiments in HIV vaccine research centred on passively transferring HIV and SIV-specific antibodies from infected to noninfected animals, to see if this protected the recipients from infection following a subsequent viral challenge (for reviews, see [15] [16] [17] [18] [19] . Five such trials in chimpanzees are registered in the NHPVT database, and are summarised in Table 2 .
The search of the ClinicalTrials.gov database did not locate any human trials of passive antibodies to protect against or to treat HIV infection, but many reports of pre-clinical and clinical investigations of passive therapies for HIV/AIDS do exist. The NHPVT database contains five entries for trials of this type, and all but the earliest (NHP .361; registered in 1988) either prevented or controlled HIV infection in chimpanzees ( Table 2 ). Murthy et al. (17) referred to passive immunisation studies in chimpanzees involving a total of five different antibodies. Four of them were protective; the one that was not protective did, however, delay the onset of infection (20) . HIV human hyperimmune immunoglobulin (HIVIG) had been shown to protect chimpanzees from HIV challenge when administered both pre-and post-exposure (21) , an observation that prompted the authors to conclude that induction of humoral immunity was a pre-requisite for any HIV vaccine, but that cell-mediated immunity may not be needed -a conclusion that is unfounded in humans. Stiehm et al. (22) , in contrast, assessed the effects of HIVIG in 30 HIV + children, where CD4 cell levels, plasma RNA copy number, cellular virus load, immunoglobulin levels, and neutralising antibody titres were only minimally affected and clinical status was not changed. A soluble CD4 analogue called 'CD4-IgG' (also known as CD4 immunoadhesin, in which CD4 is combined with an immunoglobulin for stability) was also protective in chimpanzee experiments (23) . Trials in humans, however, suggested no evidence of clinical benefit: for example, a Phase I trial revealed that CD4-IgG did not augment the effects of the HIV inhibitor drug, azidothymidine (AZT; 24) , and a Phase I/II investigation revealed a slight improvement of T-helper cell function, but no clinical benefit (25) . Arguably, these difficulties may be expected, because HIV + individuals have high levels of soluble CD4 in their blood, even in quite advanced AIDS, suggesting it has little or no effect on progression of the disease.
More recently, Armbruster et al. (26, 27) described Phase I clinical trials of three human monoclonal antibodies (hMAbs), in which they were safe and well tolerated. One of these antibodies had been shown to delay seroconversion in chimpanzees some time previously (16) , and a paper reported a proof-of-principle human study (though the evidence is considered to be 'circumstantial'; 28) , showing that a cocktail of the same hMAbs could delay viral rebound in HIV-infected patients whose antiretroviral therapy has been interrupted. There were major caveats, however: the trial was neither randomised nor blinded; only two of eight chronically infected patients showed rebound delay; the antibodies used had to be highly potent and used at a high dose; and, there was evidence of rapid escape.
Nevertheless, in spite of these caveats, it is claimed that the findings from these experiments, in which the transferred antibodies protected chimpanzees against HIV-1 infection when administered immediately prior to or after viral challenge, directed the initial push toward an HIV vaccine involving recombinant HIV envelope proteins to induce the production of HIV neutralising antibodies (29, 30) . The status of this approach to vaccine development is considered in detail below (see 'Recombinant Proteins').
Attenuated/inactivated virus vaccines
Live attenuated virus vaccines have historically been used with great success against many diseases (including measles, mumps and rubella), due to their induction of strong and broadly reactive humoral and cell-mediated immune responses (31) . Despite this, putative AIDS vaccines of this class have been limited to NHP studies and have not entered clinical trials (32, 33) . This is due to concerns over reversion to virulence, recombination with other virions to form new, potentially highly- pathogenic strains, and the dangerous consequences of integration of the attenuated virus genetic material into the host genome (summarised by Van der Ryst; 29) . Although these concerns are largely based on the results of macaque experiments, there are convincing human data: immunosuppression has occurred in humans exposed to attenuated HIV via blood transfusions; and residual infectivity caused over 200,000 people to be infected by live polio virus during vaccination in the infamous Cutter incident (30) . Inactivated AIDS vaccines, however, have been tested clinically. Ten trials are registered, including two in 2005 for the Remune vaccine (formerly known as HIV-1 Immunogen), which comprises whole HIV particles that have been chemically and radioactively inactivated, with their envelopes removed to preclude the infection of T-cells. The rationale is to use this vaccine as a therapeutic intervention, probably in tandem with anti-retroviral drugs, in people already infected with HIV, in order to control the activity of the virus by stimulating cell-mediated immunity and thus reduce the rate of progression of AIDS.
However, Remune has failed to produce promising results in human subjects. Two of the ten trials (the most recent of which was registered in 2005) were terminated, and a large Phase III study failed to find any additional benefit from Remune, when used to augment anti-HIV drugs (10) . Even more recently in July 2007, Remune's manufacturer (Immune Response Corporation) announced the discontinuation of its HIV Vaccine Development Program altogether, following a disappointing clinical trial of Remune and its second-generation successor vaccine, IR103 (consisting of Remune and an adjuvant known as Amplivax) (34) . The results of human trials have therefore prompted negative opinions concerning this approach in a number of reviews, for example, "…inactivated viruses have not been capable of inducing adequate immunoresponse" (35) .
There is evidence of enhanced immune response in chimpanzees following vaccination with a gp120depleted inactivated HIV-1 (36) , and the NHPVT database contained one record of a chimpanzee trial of this type of vaccine (Table 2 ). In 1993, inactivated whole HIV-1 was tested along with three different adjuvants (37) , in three groups of three chimpanzees -but even the group with the 'best' immune responses became infected when challenged shortly after their sixth immunisation. It is therefore assumed that vaccines of this type may have proceeded to clinical trials based on more-positive results from experiments with other species.
Recombinant proteins
Immunogenic proteins have constituted a significant area of AIDS vaccine research, accounting for 49 (25%) of the 197 registered trials, though just seven of them have been registered since 2004. These 49 trials have tested just nine different vaccines (or 15 vaccines, if similar proteins from different strains of HIV are included). Vaccines tested have comprised the following: gp160 (expressed in Vero cells [epithelial cells from African green monkeys], in Sf9 cells by using recombinant baculovirus, and from strains IIIB and LAI-2); gp120 (strains SF2, MN, IIIB, A244 and W61D, and also Env 2-3 [a yeast-derived gp120 combined with an adjuvant emulsion]); NefTat fusion protein; Tat protein; EnvPro (an engineered and stabilised form of gp160 with adjuvant); and p24 protein (from the gag gene). Other proteins, such as the viral polymerase and regulatory proteins Rev and Vpr, have also been subject to evaluation. Perhaps the bestknown candidate vaccines from this class are the AIDSVAX vaccines (AIDSVAX B/B and AIDSVAX B/E), each comprising two gp120 proteins from different HIV clades.
The relatively high number of trials for the number of recombinant protein vaccines is due to combination of the immunogenic proteins with a variety of adjuvants, as well as the testing of different routes of administration. Notably, just nine of the total of 49 trials have not been completed. Of the 40 completed trials, just four had progressed beyond Phase I. Of the nine trials that had not been completed, three were prematurely terminated. Almost all of the trials (45/49) involved recombinant envelope protein, since this protein is the primary target for neutralising antibodies in infected persons (38) . Although invariably immunogenic, the antibodies induced have tended to be very clade-specific and have failed to neutralise primary isolates of HIV derived from the blood of patients. Another major problem with the use of stand-alone vaccines of this type was quickly revealed -they rarely induced the cell-mediated arm of the immune system, which has been regarded as an essential requirement for an HIV vaccine for some years (39) .
Seven chimpanzee trials of recombinant proteins were listed in the NHPVT database, in which eight vaccines were tested ( Table 2 ). All eight tests showed the vaccines to be immunogenic (though one test gave mixed results). Three of the eight tests did not result in protection (involving two gp120 and one gp160 vaccine), whereas three tests did result in protection (all of which involved gp120 vaccines). One of the tests (with a gp120 vaccine) gave mixed results (where one animal was protected, but another was not protected completely), and another test did not assess protection from infection.
Notable vaccines reported in the scientific literature include recombinant gp120 vaccines that protected chimpanzees from subsequent challenge (40) (41) (42) , but that failed to show protection in The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees. The final column indicates whether the vaccine was primarily preventive (P) or therapeutic (T). Interventions are shown in plain text, underlined, or bold text, to indicate which vaccines were previously tested in chimpanzees, given the caveat that the frequent poor quality of vaccine information requires this to be an educated guess: Plain text = no evidence found for prior testing in chimpanzees; Underlined text = similar but not identical to vaccine tested in chimpanzees (e.g. same plasmid containing same HIV gene among other genes; different adjuvant; etc.); Bold text = identical vaccine tested in chimpanzees. human trials (43) . The ability of recombinant gp160 protein to confer protection was also shown in chimpanzees (44, 45) , as it was in other studies where a variety of vaccines were also protective to chimpanzees, such as whole inactivated virus, recombinant vaccinia-gp160, the recombinant proteins p18 gag, p27 nef and p23 vif, and peptide immunogens (46, 47) . This protection in chimpanzees extended to challenge with HIV-infected lymphocytes, as well as with free virus (48) . Recombinant gp160 protein was also protective in chimpanzees when boosted with V3 peptides (49, 50) . Also, one of the two aforementioned AIDSVAX vaccines, produced by VaxGen, was the first candidate HIV vaccine to complete a Phase III trial (43) , closely followed by the other. AIDSVAX B/B (comprising gp120 envelope proteins from two clade B strains of HIV, MN and GNE8) failed to protect more than 5000 trial participants (mainly gay men) at high risk of HIV infection (51) , and AIDSVAX B/E (comprising gp120 from strains MN and A244 [clade E]) failed to provide protection against HIV infection for over 2500 users of injected drugs in Thailand (52) , despite repeated booster immunisations throughout the study. These failures occurred despite the fact that AIDSVAX achieved the greatest immune response of any vaccine of this type (35) .
The dearth of active clinical trials of this kind of vaccine, coupled with high-profile failures, has prompted some to consider that the concept of the induction of neutralising antibodies as an HIV vaccine strategy has 'run aground' (53) . Evidence suggests this was recognised by many scientists some time ago, there having been a distinct re-focusing of efforts to develop an effective vaccine toward other approaches, as well as an admission that recombinant proteins could be used only as part of a 'prime-boost' vaccine regimen.
Peptide/lipopeptide vaccines
Peptide/lipopeptide vaccines constitute 14 (7%) of the 197 registered clinical trials, and involve nine different vaccines. They contain small fragments of HIV proteins, rather than the complete molecules, which makes them simpler and cheaper. These fragments often contain the most immunogenic parts of the HIV proteins, targeting an immune response to dominant T-cell epitopes and neutralising determinants (54), and several peptides from different strains of HIV can be contained in one vaccine. More recently, they have been combined with lipid molecules to form 'lipopeptides', in order to increase their immunogenicity (55) .
In common with recombinant protein vaccines, most trials of peptides/lipopeptides were registered, and therefore took place, in and around 1999. Just four trials have been registered since 2004. All but one (13/14) of the trials are Phase I trials; the exception is a Phase II trial of the LIPO-5 vaccine, which is listed as no longer recruiting participants. As may be expected due to the lack of trial progression, and in common with trials of recombinant protein vaccines, success has not been reported (2, 35, 56, 57) , despite, for example, reports of potent and long-lasting B-cell and T-cell responses to lipopeptide immunisation in chimpanzees (58) .
No chimpanzee trials of this type of vaccine were listed in the NHPVT database.
Virus-like particles
Virus-like particles (VLPs, also known as 'pseudovirions') can be generated by the in vitro or in vivo (such as in transfected cells) production of HIV-1 viral proteins, which can spontaneously assemble into particles. Only two registered trials were found in ClinicalTrials.gov, which were both Phase I trials registered in 1999. One of these ('HIV-1 Pseudovirion' vaccine) was terminated prior to completion.
Young et al. (31) , however, report that the other vaccine (HIV p17/p24:Ty-VLP) has also been tested in a Phase II trial (59) . In contrast to results obtained in mice, vaccinated individuals had low levels of both humoral and cell-mediated immunity. This vaccine also showed no significant effect on disease progression in HIV-infected volunteers in a long-term follow-up study (60) . Young et al. (31) also cite another Phase I trial with VLPp24 vaccine, which failed to augment immunity to HIV in infected patients (61) .
DNA vaccines
Twenty-five (13%) of the 197 registered trials involved 14 different DNA vaccines, whereby plasmids containing HIV genes are used to induce immunity to the virus when injected intramuscularly. Cells exposed to such plasmids 'ingest' the DNA, which is then transcribed and translated by the host cells to produce the cognate viral proteins. When 'proof of concept' was initially demonstrated by injecting DNA into the muscles of mice (62), it was subsequently shown that proteins produced in this manner could induce significant humoral and cellular immune responses (63) (64) (65) .
The NHPVT database contained three records of DNA vaccine trials in chimpanzees (NHP .226, NHP .202 and NHP .71), all of which demonstrated immunogenicity. One trial provided protection from HIV infection to an uninfected chimpanzee, and one vaccine induced an indefinite decrease in viral load, when used as a therapeutic vaccine for infected chimpanzees. The other trial was also ther-apeutic in nature, and also decreased viral load, though this effect was transient.
Twenty-five (13%) of the 197 registered trials examined 14 DNA vaccines. All but three of these 25 trials were Phase I trials, with the remaining three being Phase I/II trials. Just eight of the 25 trials had been completed at the time of writing, and one trial of a gag DNA vaccine registered in 2005 has already been terminated.
Many researchers thought that DNA vaccination would revolutionise vaccine development for many diseases, not just for HIV. The first human trial involved HIV-1 strain MN env gp160 and rev genes (66) , and although marginal increases in anti-gp160 cytotoxic T-lymphocyte (CTL) activity were observed in a small number of volunteers, there was no change in CD4 + T-cell count or plasma viral load. Subsequent trials have continued to fall short: for example, plasmids encoding nef, tat or env genes have been only slightly immunogenic (67, 68) , and just three of the trials are anything other than Phase I trials (i.e. Phase I/II). This disappointment is reflected in the opinions of authors of several recent reviews on the topic: "Although immunisation with DNA plasmids that contain HIV inserts has elicited substantial cellular responses in mice and nonhuman primates, these products have been poorly immunogenic in humans." (5) ; "Plasmid DNA constructs have proved to be effective immunogens in mice for eliciting cellular immune responses and for priming antibody responses. It is now clear, however, that DNA vaccines are less immunogenic in nonhuman primates than they are in mice, and even less immunogenic in humans than in non-human primates." (69); and "Although DNA vaccines are immunogenic in mice and monkeys (including neonates), current vaccines are poorly immunogenic when administered alone to people." (70) .
There is ample supporting evidence for such opinions. DNA vaccination has been shown in numerous studies to produce strong virus-specific immune responses, and to be protective against HIV infection in chimpanzees (71) (72) (73) (74) .
The initial failures with 'native' DNA vaccines have led to efforts to augment vaccine DNA expression by using co-expressed cytokines (notably interleukin [IL]-12 and IL-15; 5) and adjuvants (55, 75, 76; see Table 1 ), by improving DNA delivery techniques (77, 78) , by using the DNA vaccines in a combination 'prime-boost' approach, and by using a variety of genetic techniques, such as promoter modification and codon optimisation (79, 80) .
Recombinant microbial vaccines (RMVs)
RMV trials constitute 21% (or 41/197) of all registered clinical trials, and involve the use of microorganisms that have been genetically engineered to include HIV genes. Almost all of the vectors are viral, though the bacterium, Salmonella typhi, has also been used. The principle involves using the microorganism to carry the HIV genes into the cells of the vaccinated individual, where those genes are expressed and rendered subject to host immune responses via presentation on the host cell-surface in association with Major Histocompatibility Complex (MHC) Class I molecules.
Thirty-seven of the 41 trials have been of individual vaccines, and four involved more than one type of vaccine in this class. Collectively, 24 different vaccines have been tested in these trials, with 27 Phase I, 11 Phase II, two Phase I/II and one Phase III trials initiated. RMVs are a relatively new approach to the development of an HIV vaccine, reflected in the fact that just ten clinical trials have reached a conclusion, and that, excluding the canarypox class of vaccines, all but one of the trials were registered in or after 2003. It seems, however, that the primary emphasis of HIV trials has moved toward this approach (5), given the recent high profile failures of recombinant-protein vaccines in Phase III trials, for example (81) (82) (83) .
Of the concluded trials, seven of the ten were completed, two were terminated, and one was suspended.
Adenovirus
Twelve trials involving five adenovirus vaccines (based on the 'common cold' virus) are registered, constituting 29% of all the trials involving RMVs. This approach has received much attention, for a number of reasons: adenoviruses induce mucosal immunity, which should help prevent HIV infection at genital/rectal sites; they infect dendritic cells, leading to the efficient presentation of viral antigens; and they elicit long-term humoral and cell-mediated immunity (84) . They have also given successful results, including protection from HIV infection, in studies in several non-human species, including nonhuman primates, for example macaques (85) and chimpanzees (86) (87) (88) . A combination approach, involving recombinant adenovirus-gp160 and gp120 proteins, was also successful in chimpanzees, protecting them from even high-dose challenges of HIV after only a few immunisations (89) (90) (91) .
Clinical work in this area is fairly advanced, with half of these trials being in Phase II, though two of them have been terminated. These terminated trials involved Merck's V520 vaccine, which comprises a recombinant Ad5 adenovirus containing the HIV gag, pol and nef genes. Despite being widely considered by experts as "one of the most promising to be tested on people so far" (92), trials of the vaccine were terminated in September 2007, when an interim analysis prior to the planned completion in 2008 concluded that the vaccine simply wasn't working. It had failed to protect thousands of volunteers from HIV infection, and also to reduce HIV levels in people already infected. Disturbingly, more HIV infections were present in those who had been given the vaccine, as compared to those given the placebo (24 versus 21, respectively), with those who had been in the trial longer and who had received more injections faring even worse, with 19 cases of HIV infection after vaccination versus just 11 after placebo treatment (93, 94) . As this was the first viral-recombinant vaccine to reach this stage of clinical trials, and the first to examine cell-mediated immunity alone in humans (53) , some believe that it raises questions about whether the use of RMVs can be successful at all, particularly as vaccines based on adenovirus have appeared to be the most immunogenic in terms of the percentage of human responders and the level and duration of T-cell responses (95) .
Adeno-associated virus
Just one trial was identified involving recombinant adeno-associated virus (AAV), which was registered in 2007, although it commenced in 2003. This Phase I trial has been completed, and evaluated an AAV containing clade C gag, pro, and rt HIV sequences.
Vaccinia
Of 40 single-intervention recombinant microbial vaccine trials, eight, involving seven vaccinia-virus based interventions, were identified, though just one trial has been completed. All but two are Phase I trials, with one trial at Phase I/II and another at Phase II.
Three trials involving recombinant vaccinia vaccines in chimpanzees were identified in the NHPVT database. Although all the vaccines were immunogenic, the two trials that took place in the 1980s did not show protection from HIV infection. The other trial took place more recently in 2000, but only assessed immunogenicity.
Modified Vaccinia Ankara virus (MVA) forms the basis of many recombinant vaccinia approaches to an HIV vaccine, because of its high degree of attenuation and consequent good safety profile. Initial results in human trials, however, have been disappointing, with cell-mediated immunity being elicited in only a small minority of individuals (96) , despite promising results in macaques (5) . Human trials that include MVA vaccines as part of a prime-boost strategy have also been disappointing (6) .
Canarypox
Vectors based on the canarypox virus constitute the biggest proportion of trials involving RMVs -alto-gether around a third of the total (13/41, or 32%), five of which have progressed to Phase II; the remainder are Phase I trials. These trials involved four different vaccines, all based upon the ALVAC vector developed by Sanofi-Pasteur (based on an attenuated strain of canarypox). In principle, these vectors are highly fitfor-purpose: they replicate only in the cytoplasm of infected cells (minimising the risk of integration with the host genome and any ensuing problems); replication is restricted; and they are sufficiently safe and well tolerated in humans (97, 98) . Further, they can accommodate large gene insertions (99) , and they can stimulate both humoral and cell-mediated immune responses of long duration in humans (100) (101) (102) .
An early Phase I/II trial ended in disappointment, however, when a gp160 vaccine (ALVAC-HIV) failed to enhance both humoral and cell-mediated immune responses (103) . Looking at the register of clinical trials (Table 1) , further failures with other ALVAC trials appear to have followed. Focus seems to have shifted to other approaches, signalled by the low number of trials registered in recent years (compared to 1999-2001, for example). This is true, not just for trials solely involving canarypox, but also for the many trials of AIDS vaccines involving recombinant canarypox in combination with other approaches such as the use of DNA and recombinant proteins. In addition, it has been reported that five different canarypox vaccines have been tested in around 11,500 volunteers (5) . Though well tolerated, these vaccines did not induce durable immune responses, and were immunogenic in fewer than 20% of the subjects (104) .
Canarypox vaccines have also been tested in children, with similarly disappointing results. For example, the vCP205 and vCP1452 vaccines were given to very young infants of HIV + mothers; again, they were well tolerated, but produced humoral and cell-mediated immune responses either not at all, or of a very low magnitude (105) . Comparison with chimpanzee vaccinations is difficult, as just one such trial is listed in the NHPVT database, involving three animals. In this instance, the vCP250 vaccine was immunogenic, and protected one of the two experimental animals from cell-associated viral challenge. It did not, however, protect this chimpanzee against subsequent infection with cell-free HIV ( Table 2) .
As mentioned previously, many trials have used canarypox in combination with other vaccine candidates -though this has not resulted in an improvement in efficacy. For example, vCP1452 has been administered with an AIDSVAX B/B boost to infants, but enthusiasm for further trials was limited due to 'modest immunogenicity' (70) .
Others
Two clinical trials involved the use of Venezuelan Equine Enceph alitis alphavirus (VEE) as a vector.
Both Phase I trials, they assessed the vaccine AVX101, which contains the HIV gag gene as an immunogen. Another trial, registered in 2003 but not yet recruiting participants, proposes to evaluate a vaccine based on recombinant Salmonella typhi containing the HIV gp120 gene.
Three clinical trials, all registered relatively recently (2004) (2005) (2006) , involved more than one type of RMV. Two of the three trials investigated combinations of vaccinia-based (MVA) and fowlpox-based vaccine pairs, each containing the env/gag and tat/rev/nef HIV genes. The status of the earlier of the two trials is 'no longer recruiting,' though the details state that all vaccinations were discontinued in Novem ber 2006, and the other trial has been suspended. The third trial will assess a 'prime-boost' intervention involving an initial DNA plasmid vaccine 'prime', followed by a Modified Vaccinia Ankara (MVA) 'boost' (this approach is described in more detail later in this review).
Autologous cells
Dendritic cells are one of the first ports-of-call for the virus upon infection. They are locally infected at the entry site of the virus, before proceeding to the lymph nodes where they infect CD4 + T-cellsthe principal target of the virus, the attrition of which leads to AIDS. Consequently, dendritic cells are central to the induction of the immune response to HIV infection, though their response is known to decline with time (106) (107) (108) (109) .
With this in mind, six trials have been registered that involve two types of autologous-cell approach to therapeutic HIV vaccination: five with dendritic cells, and the other with T-cells. The former strategy involves harvesting a patient's own dendritic cells and loading them in vitro with HIV peptide antigens or inactivated autologous virus. The latter T-cell based vaccine is prepared from autologous Tcells, which have proliferated following exposure to recombinant CD4. The cells are then introduced back into the patient, in the hope that they can better activate immune responses that can control the infection. Early results in humans are considered promising, at least against the same viral strain used to produce the cell-based vaccine (110) , though this must be interpreted with caution, as any efficacious vaccine must elicit immune responses against diverse strains of HIV.
No chimpanzee trials of this vaccine type were listed in the NHPVT database, though the immunogenicity in chimpanzees of dendritic cells pulsed with test antigens has been reported in the scientific literature, with somewhat equivocal results (111, 112) , and a T-cell vaccine for hepatitis C has been tested in chimpanzees, which elicited immunity against heterologous hepatitis C virus (HCV; 113).
Multi-component vaccines and prime-boost strategies
Due to negative results in many trials involving single vaccines of all types, much focus has shifted toward the development of multi-component vaccines, in so-called 'prime-boost' strategies. This type of intervention aims to enhance the immune response to a particular antigen, and to induce both the humoral and cell-mediated arms of the immune response by administering it in successive, but slightly different, ways -especially when using just one route/vaccine type has not proved sufficiently immunogenic. The rationale is to 'prime' the immune system with the first antigen (for example, a DNA vaccine or recombinant adenovirus or poxvirus), and then to 'boost' the immune response to it by using, for example, another RMV or protein.
Fifty clinical trials were identified in this category ( Figure 5) , with the most prevalent combinations being canarypox-protein (15 trials), adenovirus-DNA (11 trials) and vaccinia-protein (7 trials). Given the relatively recent nature of this type of approach, the majority of the trials are Phase I trials (31/50), with just seven Phase II and two Phase III trials. One of the Phase II trials, involving a canarypox-lipopeptide vaccine (ALVAC HIV-1433 and LIPO-6T), was terminated, and a recent publication revealed that HIVspecific CD4 + T-cell responses did not change in immunised patients relative to controls, that the vaccination had only a transient effect on interferongamma-producing CD8 responses, and that the viral rebound after treatment interruption was similar in immunised patients and controls (114) . The Phase III trial, involving a canarypox-inactivated virus vaccine (vCP1452 and Remune), was registered in 2000 and has been completed (without success), and the other trial, involving a canarypox-protein vaccine combination (vCP1521 and AIDSVAX gp120 B/E), commenced in 2003 and is no longer recruiting.
Despite this Phase II termination and the lack of reported success surrounding the Phase II trials, much hope is held in some quarters for this strategy, largely based on pre-clinical studies in monkeys, where prime-boost vaccines are often more potent than either vaccine alone (55) . The NHPVT database lists four chimpanzee trials of multi-component vaccines, one of which tested two different vaccine combinations. All five combinations were immunogenic. One of the trials (NHP .465), involving an adenovirus prime and an oligomeric gp140 boost, did not assess protection from infection, but all the other vaccines demonstrated protection, except one, which comprised a vCP125/gp160 combination (trial NHP .167). In addition to those studies registered with the NHP database, Girard et al. (47) reported the protection of chimpanzees from HIV infection following immunisation with "a variety of HIV-1 immunogens -followed by rgp160 and V3 peptides", including combinations of enve- lope antigens. This all contrasts with findings in humans, however, where "observations in early phase clinical trials in humans have not been promising", due to adverse reactions and lack of diversity in the immune response (115) . Naturally, not all the vaccines tested in chimpanzees have provided protection against HIV challenge. One of the vaccine combinations tested by Girard et al. (47) , for example, described a combination strategy involving recombinant gp160canarypox and recombinant gp160 protein, that failed, although the low dose of the vaccine was postulated as a factor.
Summary and Discussion
To date, 85 candidate AIDS vaccines have been tested in 197 clinical trials, comprising several main types -from inactivated virus vaccines through DNA plasmids to recombinant proteins and viruses. Just 12% of these trials have reached Phase II, only seven (3.5%) have reached Phase III, and altogether, 18 trials were prematurely terminated. None has been successful.
Early optimism has transformed into a realisation that we are decades away from even a partially effective vaccine in humans. The monumental financial and human resources allocated to vaccine development have resulted in dozens of safe and effective vaccines only for chimpanzees and monkeys with laboratory-induced infections. Hope that the use of NHPs will lead to the successful development of a vaccine for humans is tempered by the recent, high-profile failures of the AIDSVAX and V520 (Merck) candidates in extensive and late-stage clinical trials. Notably, the latter increased the risk of HIV infection compared to the placebo -and it is not alone in this respect: previously, gp120-based vaccines increased the risk that vaccinated people would develop an infection or progress to AIDS post-infection (116) .
Furthermore, the limited critical appraisal to date of the favoured SIV/chimeric SIV-Human Immunodeficiency Virus (SIV/SHIV)-macaque model, has been unfavourable (35, 53, 56, (117) (118) (119) (120) (121) , stimulating a desire for models of greater relevance. While some scientists associated with chimpanzee research advocate a resumption of their use, such use must be objectively and independently evaluated.
Poor performance of the chimpanzee model in the development of AIDS vaccines
This analysis expands on previous data that underlined the poor performance of chimpanzees as models in HIV/AIDS research, evidenced by a large number of negative opinions and comments toward it and by the significant withdrawal of NIH funding for it. The evidence provided, based on a comparison of human and chimpanzee responses to AIDS vaccines, gives further argument against a return to chimpanzee-use in this field.
Contrary to claims that chimpanzees play a "critical role in the testing of potential [HIV] vaccines" and that they "are still important for testing vaccines aimed at preventing HIV-1 infection or reducing the virus load in infected individuals" (14) , this review shows that neither claim has any scientific foundation. Many vaccines of many types have been tested in chimpanzees prior to clinical trials, and their correlation to, and predictive nature for, the human response is demonstrably poor. Chimpanzees have been protected from HIV infection passively via the transfer of antibodies (both pre-and post-exposure), which prompted the (now highly unlikely) suggestion that cell-mediated immunity is not necessary. Passive protection has also been induced by a soluble CD4 analogue. Neither approach has been successful in humans. Attenuated vaccines have provided protection in chimpanzees, but have not been tested clinically due to safety concerns. Inactivated-virus vaccines have disappointed clinically, and while results were similarly negative in chimpanzees, these results were of little relevance and did not prevent inactivatedvirus vaccines from progressing to clinical trials. Negative results with recombinant protein vaccines in chimpanzees (Table 2 ) also did not stop these vaccines progressing to further testing and clinical trials (122) .
While RMVs have been disappointing in humans, including the Phase III AIDSVAX trials, many (excluding a couple of early efforts) provided protection from HIV infection in chimpanzees. Clinical trial success with peptide and lipopeptide vaccines has not been reported, despite prior evidence of potent and persistent cell-mediated immune responses in chimpanzees. Both preventive and therapeutic DNA vaccination have been successful in chimpanzees. Optimism for success in humans was high, but poor immunogenicity has led to recent disparaging comments. Recombinant adenovirus vaccines have elicited protection from HIV infection in chimpanzees, both alone and in combination with recombinant HIV proteins. However, the situation in humans may be grave, with possibly "the most promising [vaccine] tested on people so far", in the form of Merck's V520 vaccine, not only ending in the termination of its Phase IIb trial, but increasing the risk of HIV infection for its recipients.
Due to the diminished use of chimpanzees in pre-clinical testing for reasons discussed above, some types of vaccines have not been widely tested in chimpanzees. Immunogenicity has been demonstrated in chimpanzees with vaccinia-based vaccines, however -which is true in only a small minority of humans in clinical trials so far. Similarly, canarypox vaccines have induced pro-tection from cell-associated (but not cell-free) virus challenge in chimpanzees, but several vectors have been immunogenic in a small proportion of clinical-trial volunteers, including children, even as part of prime-boost regimens -and then only poorly so. Some prime-boost vaccines, involving a variety of immunogens, have proven positive in chimpanzees, again in contrast to humans, in which the results have been disappointing, replete with adverse reactions and lack of diversity in the immune response.
Problems with the chimpanzee model: Reasons for its lack of relevance
Researchers continue to rely on results largely from macaques infected with SIV or SHIV (an SIV/HIV hybrid), despite important differences between SIVinfected macaques and HIV-infected humans (53, 117) . Significant disparities exist in virulence, pathology, genetics, protein function, infection and host response (118) . Two recent reviews stated that, "efficacy of HIV-1 based vaccines cannot be directly evaluated in the SIV model" (119) and that, "this has not proven a practical animal model for studying vaccines" (35) , the latter citing significant supporting evidence (56, 121, 122) . A 2007 review stated, "When it comes to testing HIV vaccines, only humans will do" (53); another cited, "the persistent view held by many that there is no predictive animal model for HIV infection in humans" (123) , and another that, "No animal models faithfully reproduce... HIV-1 infection and disease in humans, and the studies of experimental vaccines in animal models... have yielded disparate results" (124) .
Yet the rhesus macaque became the model of choice following the discovery in 1987 that SIV caused an AIDS-like disease in these animals (125) . It replaced the chimpanzee, widely used in AIDS research for several years previously but which had "had problems from the get-go" (125) -vis-à-vis practicality (the significant costs of using and maintaining chimpanzees, including user's fees of $50,000+ per animal), statistical significance (few animals could be used in each experiment, giving unreliable results), and species differences (HIV infection rarely progresses to AIDS-like illness in chimpanzees) "undermining the model's reliability" (125) . The latter problem of scientific unreliability is, from a human perspective, most worrying. If years of chimpanzee use in HIV/AIDS research have not led to tangible progress and improvements clinically, then they represent a waste of limited resources and have done little to alleviate human suffering, as there is still no AIDS vaccine and none is imminent. A brief summary of the known differences between human and chimpanzee HIV infection and ensuing pathology may explain why.
Chimpanzees have higher baseline levels of CD8 + T-cells and a higher ratio of CD8 + /CD4 + T-cells, and their percentage of beta-chemokine-positive CD8 + T-cells and natural killer (NK) cells is significantly higher than in uninfected humans. Chimpanzees do not typically produce increased numbers of these cells following HIV infection, unlike humans (126) . As these are the cells that attempt to control infection, and the latter are the cells infected by HIV-1 and subsequently destroyed by the virus, this is critical. Unlike in humans, it is difficult to routinely isolate HIV from the plasma and sera of infected chimpanzees (127) , and chimpanzee CD4 + cell numbers do not drop dramatically over the course of HIV infection, with remarkably few exceptions. Instead, detectable plasma HIV decreases and eventually becomes undetectable (117) . With perhaps only one exception, HIV infection of chimpanzees does not result in a significant decline in CD4 + T-cell levels, immunodeficiency and AIDS-like illness, as in humans. The exception was Jerom ('Chimpanzee C499'), who was infected with three different isolates of HIV-1 over ten years and suffered a progressive decline in CD4 + T-cells and developed AIDS-like symptoms, caused by a quasispecies of HIV that had mutated to become more pathogenic (128) . Notably, Jerom's blood, though it caused a similar decline in CD4 + T-cells in other chimpanzees transfused with it, did not cause them to develop a similar disease (129) .
These differences, difficulties, and the lack of a vaccine led many scientists to conclude that chimpanzees should have no place in the quest for an AIDS vaccine. In 1994, the Handbook of Laboratory Animal Science called primate models of AIDS "unsuccessful" (130) . The NIH AIDS Research Program Evaluation Task Force cited the "limited utility of the chimpanzee model" and recommended "redirecting monies currently expended in the less relevant chimpanzee model" (131) . The latter was put into practice: AIDS-related chimpanzee studies fell from almost 30 studies in 1998 to four in 2005. Thomas Insel M.D., former director of the Yerkes Regional Primate Center, noted that 15 years of work in chimpanzees has produced little data relevant to humans, stating "I can't tell you what it is that those [chimpanzee] studies have given us that has really made a difference in the way we approach people with this disease [HIV/AIDS]" (132) ; and a review article in 2000 opined "Defending the usefulness of the chimpanzee as a model for HIV research has not only become a difficult task, but also a controversial one" (133) .
These realisations came too late. At least 198 chimpanzees were deliberately infected with HIV prior to 1997 (134) , and around 1,300 chimpanzees are currently in US laboratories, due in large part to over-breeding for AIDS research in anticipation of their use in this area, and despite a breeding moratorium being in place for the past decade.
Ethical issues associated with chimpanzee use
Ethics must be considered alongside scientific relevance, because of the cost of chimpanzee use, and because chimpanzees are a 'special case', testified to by public and scientific opinion, and policies and laws in the US and throughout the world. The passage of the CHIMP (Chimpanzee Health Improvement, Maintenance and Protection) Act in the USA in 2000, as well as the fact that many countries ban or restrict the use of great apes, acknowledges a different moral status for chimpanzees. Both scientists and the public acknowledge that chimpanzees have advanced cognitive abilities, and social and emotional needs. They are capable of reasoned thought, abstraction, generalisation and symbolic representation; have a concept of self; exhibit a broad range of emotions; experience mental as well as physical pain; and can be taught to communicate in human languages such as American Sign Language, and demonstrate complex nonverbal communication patterns among themselves (135) (136) (137) (138) (139) (140) (141) (142) . In captivity, they show a range of behavioural abnormalities and measurable signs of distress (psychopathology; 143, 144) . The widely-respected researcher and advocate for chimpanzee welfare, Jane Goodall, stated in a letter to Science that, "It is their humanlike behaviours that most fascinate people: their tool-using and making abilities, the close supportive bonds among family members… and their complex social interactions -the cooperation, the altruism, and the expression of emotions like joy and sadness" (145) .
Conclusions
The evidence presented in this study includes: -substantial differences between chimpanzee and human responses to HIV infection and the course of the disease;
-expert opinion;
-past failures as a vaccine model;
-progression of vaccines to clinical trials despite negative results in chimpanzees;
-increasing knowledge of chimpanzees' cognitive and emotional capacities; and -increased ethical issues surrounding chimpanzee research.
From this evidence, it is concluded that chimpanzees have no justifiable role in AIDS vaccine research and testing. Advocating the resumption of their use defies the burden of scientific evidence of repeated failures involving their use. If chimpanzees were not reliable, predictive and fit for purpose from 1990 to 2008, what justification is there for a resumption of their use? A 2006 review of AIDS vaccine testing, when referring to chim-panzee trials of inactivated-virus and DNA vaccines, concluded "it proved difficult to examine the effect of these vaccines, due to the general lack of clinical progression to immunodeficiency in this animal model and the prohibitive cost of these experiments" (7) . Some twenty years after chimpanzees were the mainstay of AIDS vaccine testing, an efficacious vaccine for human use remains unavailable and not imminent. The use of chimpanzees has largely been abandoned for scientific and cost-benefit reasons. As millions of humans continue to become infected or die each year, the continued use of chimpanzees in AIDS research is scientifically unwise and ethically unjustifiable.
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